サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：ヒト免疫不全ウイルス治療薬の世界市場：成長、将来展望、競合分析 (2025年～2033年)
市場調査レポート
商品コード
1645228

ヒト免疫不全ウイルス治療薬の世界市場：成長、将来展望、競合分析 (2025年～2033年)

Human Immunodeficiency Virus Therapeutics Market - Growth, Future Prospects and Competitive Analysis, 2025 - 2033

出版日
ページ情報
英文 178 Pages
納期
即日から翌営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
ヒト免疫不全ウイルス治療薬の世界市場：成長、将来展望、競合分析 (2025年～2033年)
出版日: 2024年12月10日
発行: Acute Market Reports
ページ情報: 英文 178 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ヒト免疫不全ウイルス (HIV) 治療薬市場は、後天性免疫不全症候群 (AIDS) を引き起こすウイルスであるHIVの治療薬や治療法の研究、開発、流通に重点を置く製薬産業の一分野です。1980年代に発見されて以来、HIV/AIDSは公衆衛生上の重大な脅威となっており、世界中で数百万人が死亡しています。効果的な治療法に対する一貫した需要と医学研究の進歩が相まって、この市場は感染症治療薬の最前線へと押し上げられました。ヒト免疫不全ウイルス治療薬市場は、2025年から2033年にかけてCAGR 1.3%で成長すると推定されます。

促進要因：世界のHIV/AIDS罹患率と有病率の増加

HIV治療薬市場成長の紛れもない主な要因は、世界のHIV/AIDS患者数の継続的な増加です。国連合同エイズ計画 (UNAIDS) によると、2019年には世界で約3,800万人がHIVとともに生活しています。この数字の大きさは、効果的な治療に対する緊急性と需要を強調しています。さらに、特定の地域、特にサハラ以南のアフリカが不釣り合いな影響を受けており、ウイルスの蔓延と影響と闘うための世界の取り組みが激化しています。これを受けて、多くの政府や国際機関が資金援助やイニシアチブを強化し、研究や治療薬に対する需要をさらに押し上げています。

機会：新規治療アプローチの出現

HIV/AIDSとの闘いが続く中、新たな治療法の開発が一つの大きなチャンスとなっています。近年、HIVの潜在的治療法、あるいは治療薬として、遺伝子治療やCRISPR技術への関心が高まっています。科学雑誌に掲載された最近の研究では、これらのアプローチが体内のHIVリザーバーを標的とし、根絶する可能性が示されています。これらの進歩は、従来の抗レトロウイルス療法から、より決定的で治癒の可能性のあるアプローチへのパラダイムシフトを示唆しており、市場拡大の大きなチャンスです。

抑制要因：高い治療費とアクセシビリティの問題

進歩にもかかわらず、HIV治療薬市場は、特に中低所得国において、しばしばアクセシビリティを制限する高額な治療費という抑制要因に直面しています。抗レトロウイルス治療は効果的である一方、高価であるため、発展途上地域の医療・システムが普遍的に治療を提供することは困難です。世界保健機関 (WHO) は、この格差をたびたび強調し、治療へのアクセスを向上させる進歩は見られるもの、主に先進的なHIV治療薬にかかる法外な費用のために、大きな格差が残っていると指摘しています。

課題：治療アドヒアランスと薬剤耐性

HIV治療における重大な課題の1つは、治療アドヒアランスとそれに伴う薬剤耐性のリスクです。HIV治療では、薬物レジメンを厳守する必要があり、少しでも怠ると、ウイルスが薬物に対する耐性を獲得する可能性があります。この耐性は患者の健康を脅かすだけでなく、薬剤耐性ウイルスの蔓延にもつながり、治療プロトコルを複雑にします。米国疾病管理予防センター (CDC) は、治療アドヒアランスの一貫性の欠如が原因で薬剤耐性HIV株が発生し、感染した例を挙げ、薬剤耐性が喫緊の懸念事項であると指摘しています。

薬剤の種類別の分析

薬剤の種類別に見ると、市場はブランド医薬品とジェネリック医薬品に分けられます。2024年には、ブランド医薬品がジェネリック医薬品の売上高を上回った。これらのブランド医薬品は、多額の研究開発投資、特許保護、製薬大手による大規模なマーケティングキャンペーンに支えられ、市場で重要なニッチを切り開いた。特に特許法の施行が強固な地域では、信頼性、有効性、革新性の代名詞となっていました。とはいえ、2025年から2033年にかけては、ジェネリック医薬品が最も高いCAGRを記録すると予測されています。いくつかのブランドHIV治療薬の特許が切れるにつれ、ジェネリック医薬品の普及が予想されます。これらのジェネリック医薬品は、費用対効果に優れながら効能も高く、特に中低所得国における治療アクセスのギャップを埋めることが期待され、最も急成長している分野となっています。

薬剤クラス別の分析

薬剤クラス別に見ると、HIV治療薬はヌクレオシド・アナログ系逆転写酵素阻害薬 (NRTI)、非ヌクレオシド系逆転写酵素阻害薬 (NNRTI)、侵入・融合阻害薬、プロテアーゼ阻害薬 (PI)、インテグラーゼ阻害薬、コレセプター拮抗薬でモザイク状に構成されています。NRTIは、市場での存在期間が長く、HAART (Highly Active Antiretroviral Therapy：高活性抗レトロウイルス療法) の基礎的役割を担っていることから、2024年の売上高ではトップに君臨しました。数十年にわたりHIV治療の要となってきました。しかし、2025年から2033年にかけては、最も高いCAGRを示すと予測されるインテグラーゼ阻害剤の優位性が際立つと予想されます。これらの阻害剤へのシフトは、様々な臨床試験で証明されているように、その効力、副作用の軽減、ウイルス量を急速に減少させる有効性に関連しています。

地域別の分析

地理的な面では、2024年のHIV治療薬市場は、強固な医療インフラ、高い認知度、研究開発への多額の投資を背景に、北米が最大の売上シェアを獲得しました。しかし、2025年から2033年までの10年間は、HIV有病率が高いにもかかわらずCAGRが最も高いと予測されるアフリカ地域に注目が集まりそうです。この成長は、国際的な協力関係、医療・インフラへの投資、アクセスしやすく手頃な価格のHIV治療に対する差し迫った需要によって促進されると予想されます。

競合動向

競合分野では、2025年にアッヴィ社、ベーリンガー・インゲルハイム・インターナショナル社、ブリストル・マイヤーズスクイブ社、シプラ社、ジェネンテック社、ギリアド・サイエンシズ社、メルク・アンド・カンパニー社、ヴィーブ医療社などの有力企業が席巻しました。これらの企業は、強固な医薬品パイプライン、戦略的提携、患者支援プログラムを持ち、市場を大きく支配していました。これらの企業の戦略には、積極的な研究開発、特許の取得、医薬品をより広く利用できるようにするための現地企業との提携などが含まれていることが多いです。2025年、そしてその先の2033年に向けて、市場の競合情勢はさらに多様化することが予想されます。ジェネリック医薬品の参入や、特に需要の高い地域での現地メーカーの台頭により、業界プレーヤーにとっては、協力、革新、適応性が指針となります。

目次

第1章 序文

  • 分析内容
    • 分析の目的
    • 対象者
    • 主な提供内容
  • 市場セグメンテーション
  • 分析手法
    • フェーズⅠ：二次調査
    • フェーズⅡ：一次調査
    • フェーズⅢ：有識者レビュー
    • 前提条件
    • 採用したアプローチ

第2章 エグゼクティブサマリー

第3章 ヒト免疫不全ウイルス治療薬市場：競合分析

  • 主要ベンダーの市場ポジショニング
  • ベンダーが採用した戦略
  • 主要な産業戦略

第4章 ヒト免疫不全ウイルス治療薬市場：マクロ分析と市場力学

  • イントロダクション
  • 世界のヒト免疫不全ウイルス治療薬市場 (金額ベース、2023～2033年)
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 主な課題
    • 主な機会
  • 促進要因と抑制要因の影響分析
  • シーソー分析
  • ポーターのファイブフォースモデル
    • サプライヤーパワー
    • バイヤーパワー
    • 代替品の脅威
    • 新規参入業者の脅威
    • 競争企業間の敵対関係
  • PESTEL分析
    • 政治的情勢
    • 経済的情勢
    • 技術的情勢
    • 法的情勢
    • 社会的情勢

第5章 ヒト免疫不全ウイルス治療薬市場：薬剤の種類別 (2023～2033年)

  • 市場概要
  • 成長・収益分析：2024年 vs 2033年
  • 市場セグメンテーション
    • ブランド医薬品
    • ジェネリック医薬品

第6章 ヒト免疫不全ウイルス治療薬市場：薬剤クラス別 (2023～2033年)

  • 市場概要
  • 成長・収益分析：2024年 vs 2033年
  • 市場セグメンテーション
    • ヌクレオシド類似体逆転写酵素阻害剤 (NRTI)
    • 非ヌクレオシド系逆転写酵素阻害剤 (NNRTI)
    • 侵入・融合阻害剤
    • プロテアーゼ阻害剤 (PI)
    • インテグラーゼ阻害剤
    • 共受容体拮抗薬

第7章 北米のヒト免疫不全ウイルス治療薬市場 (2023～2033年)

  • 市場概要
  • ヒト免疫不全ウイルス治療薬市場：薬剤の種類別 (2023～2033年)
  • ヒト免疫不全ウイルス治療薬市場：薬剤クラス別 (2023～2033年)
  • ヒト免疫不全ウイルス治療薬市場：地域別 (2023～2033年)
    • 北米
      • 米国
      • カナダ
      • その他北米地域

第8章 英国・EU諸国のヒト免疫不全ウイルス治療薬市場 (2023～2033年)

  • 市場概要
  • ヒト免疫不全ウイルス治療薬市場：薬剤の種類別 (2023～2033年)
  • ヒト免疫不全ウイルス治療薬市場：薬剤クラス別 (2023～2033年)
  • ヒト免疫不全ウイルス治療薬市場：地域別 (2023～2033年)
    • 英国・EU諸国
      • 英国
      • ドイツ
      • スペイン
      • イタリア
      • フランス
      • その他欧州地域

第9章 アジア太平洋のヒト免疫不全ウイルス治療薬市場 (2023～2033年)

  • 市場概要
  • ヒト免疫不全ウイルス治療薬市場：薬剤の種類別 (2023～2033年)
  • ヒト免疫不全ウイルス治療薬市場：薬剤クラス別 (2023～2033年)
  • ヒト免疫不全ウイルス治療薬市場：地域別 (2023～2033年)
    • アジア太平洋
      • 中国
      • 日本
      • インド
      • オーストラリア
      • 韓国
      • その他アジア太平洋地域

第10章 ラテンアメリカのヒト免疫不全ウイルス治療薬市場 (2023～2033年)

  • 市場概要
  • ヒト免疫不全ウイルス治療薬市場：薬剤の種類別 (2023～2033年)
  • ヒト免疫不全ウイルス治療薬市場：薬剤クラス別 (2023～2033年)
  • ヒト免疫不全ウイルス治療薬市場：地域別 (2023～2033年)
    • ラテンアメリカ
      • ブラジル
      • メキシコ
      • その他ラテンアメリカ地域

第11章 中東・アフリカのヒト免疫不全ウイルス治療薬市場 (2023～2033年)

  • 市場概要
  • ヒト免疫不全ウイルス治療薬市場：薬剤の種類別 (2023～2033年)
  • ヒト免疫不全ウイルス治療薬市場：薬剤クラス別 (2023～2033年)
  • ヒト免疫不全ウイルス治療薬市場：地域別 (2023～2033年)
    • 中東・アフリカ
      • GCC
      • アフリカ
      • その他中東・アフリカ地域

第12章 企業プロファイル

  • AbbVie Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • Genentech Inc.
  • Gilead Sciences Inc.
  • Merck & Co. Inc.
  • ViiV Healthcare
  • その他
図表

List of Tables

  • TABLE 1 Global Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 2 Global Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 3 North America Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 4 North America Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 5 U.S. Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 6 U.S. Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 7 Canada Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 8 Canada Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 9 Rest of North America Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 10 Rest of North America Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 11 UK and European Union Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 12 UK and European Union Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 13 UK Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 14 UK Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 15 Germany Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 16 Germany Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 17 Spain Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 18 Spain Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 19 Italy Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 20 Italy Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 21 France Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 22 France Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 23 Rest of Europe Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 24 Rest of Europe Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 25 Asia Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 26 Asia Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 27 China Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 28 China Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 29 Japan Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 30 Japan Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 31 India Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 32 India Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 33 Australia Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 34 Australia Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 35 South Korea Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 36 South Korea Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 37 Latin America Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 38 Latin America Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 39 Brazil Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 40 Brazil Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 41 Mexico Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 42 Mexico Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 43 Rest of Latin America Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 44 Rest of Latin America Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 45 Middle East and Africa Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 46 Middle East and Africa Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 47 GCC Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 48 GCC Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 49 Africa Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 50 Africa Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 51 Rest of Middle East and Africa Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 52 Rest of Middle East and Africa Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)

List of Figures

  • FIG. 1 Global Human Immunodeficiency Virus Therapeutics Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Human Immunodeficiency Virus Therapeutics Market: Quality Assurance
  • FIG. 5 Global Human Immunodeficiency Virus Therapeutics Market, By Drug Type, 2024
  • FIG. 6 Global Human Immunodeficiency Virus Therapeutics Market, By Drug Class, 2024
  • FIG. 7 Global Human Immunodeficiency Virus Therapeutics Market, By Geography, 2024
  • FIG. 8 Market Geographical Opportunity Matrix - Global Human Immunodeficiency Virus Therapeutics Market, 2024
  • FIG. 9Market Positioning of Key Human Immunodeficiency Virus Therapeutics Market Players, 2024
  • FIG. 10 Global Human Immunodeficiency Virus Therapeutics Market, By Drug Type, 2024 Vs 2033, %
  • FIG. 11 Global Human Immunodeficiency Virus Therapeutics Market, By Drug Class, 2024 Vs 2033, %
目次
Product Code: 120-12-24

The human immunodeficiency virus (HIV) therapeutics market pertains to the sector of the pharmaceutical industry that focuses on the research, development, and distribution of treatments and drugs for HIV, the virus that leads to Acquired Immunodeficiency Syndrome (AIDS). Since its discovery in the 1980s, HIV/AIDS has posed a significant public health threat, resulting in millions of deaths worldwide. The consistent demand for effective treatments, combined with advancements in medical research, has propelled this market to the forefront of infectious disease therapeutics. human immunodeficiency virus therapeutics market is estimated to grow at a CAGR of 1.3% from 2025 to 2033.

Driver: Increased Global Incidence and Prevalence of HIV/AIDS

The undeniable, primary driver for the growth of the HIV therapeutics market has been the continual rise in the number of HIV/AIDS cases worldwide. According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), around 38 million people were living with HIV globally in 2019. The sheer magnitude of this number underscores the urgency and demand for effective treatments. Additionally, certain regions, particularly Sub-Saharan Africa, have been disproportionately affected, intensifying the global efforts to combat the spread and repercussions of the virus. In response, numerous governments and international organizations have ramped up funding and initiatives, further driving the demand for research and therapeutics.

Opportunity: Emergence of Novel Therapeutic Approaches

As the fight against HIV/AIDS continues, one significant opportunity has been the development of novel therapeutic modalities. In recent years, there has been a growing interest in gene therapies and CRISPR technology as potential treatments or even cures for HIV. Recent studies, published in scientific journals, have illustrated the potential of these approaches to target and eradicate HIV reservoirs in the body. These advancements suggest a paradigm shift from traditional antiretroviral therapies to more definitive and potentially curative approaches, representing a significant opportunity for market expansion.

Restraint: High Treatment Costs and Accessibility Issues

Despite advancements, the HIV therapeutics market faces the restraint of high treatment costs, which often limits accessibility, especially in low- and middle-income countries. Antiretroviral treatments, while effective, can be expensive, making it challenging for healthcare systems in developing regions to provide them universally. The World Health Organization (WHO) has frequently highlighted this disparity, noting that while progress has been made in increasing access to treatment, significant gaps remain, primarily due to the prohibitive costs associated with advanced HIV drugs.

Challenge: Treatment Adherence and Drug Resistance

One of the critical challenges in HIV treatment is the issue of treatment adherence and the consequent risk of drug resistance. HIV treatment requires strict adherence to drug regimens, and any lapses can lead to the virus developing resistance to the medication. This resistance not only jeopardizes the patient's health but can also lead to the spread of drug-resistant strains of the virus, complicating treatment protocols. The Centers for Disease Control and Prevention (CDC) has flagged drug resistance as a pressing concern, citing instances where individuals, due to inconsistent treatment adherence, have developed and transmitted drug-resistant HIV strains.

Drug Type Insights

By drug type, the market can be dissected into branded drugs and generic drugs. In 2024, branded drugs overshadowed their generic counterparts in terms of revenue generation. These branded drugs, backed by heavy R&D investments, patent protections, and extensive marketing campaigns by pharmaceutical giants, carved a significant niche in the market. They were synonymous with trust, efficacy, and innovation, especially in regions with robust patent law enforcement. Nevertheless, from 2025 to 2033, generic drugs are projected to register the highest CAGR. As patents of several branded HIV drugs expire, the market is anticipated to witness a proliferation of generic versions. These generic drugs, cost-effective yet efficacious, promise to bridge the treatment accessibility gap, especially in low and middle-income countries, making them the fastest-growing segment.

Drug Class Insights

Transitioning to drug class segmentation, the HIV therapeutics landscape is a mosaic of Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Entry and Fusion Inhibitors, Protease Inhibitors (PIs), Integrase Inhibitors, and Coreceptor Antagonists. NRTIs, owing to their longer presence in the market and foundational role in Highly Active Antiretroviral Therapy (HAART), reigned supreme in revenue generation in 2024. They've been the cornerstone of HIV treatment for decades. Yet, the span from 2025 to 2033 is expected to underscore the prominence of Integrase Inhibitors, which are predicted to manifest the highest CAGR. The shift towards these inhibitors can be linked to their potency, reduced side effects, and efficacy in reducing viral loads rapidly, as documented in various clinical trials.

Regional Insights

On a geographical plane, the HIV therapeutics market in 2024 saw North America capturing the largest revenue share, driven by robust healthcare infrastructure, high awareness levels, and substantial investments in R&D. However, the decade from 2025 to 2033 is likely to spotlight the African region, which, despite its high HIV prevalence, is forecasted to experience the highest CAGR. The growth is expected to be fueled by international collaborations, investments in healthcare infrastructure, and a pressing demand for accessible and affordable HIV treatments.

Competitive Trends

In the competitive arena, 2025 had stalwarts like AbbVie Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cipla Inc., Genentech, Inc., Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare dominating the scene. These companies, with their robust drug pipelines, strategic alliances, and patient assistance programs, had a significant hold on the market. Their strategies often encompassed aggressive R&D, patent acquisitions, and forging partnerships with local entities for broader drug accessibility. As the market treads into 2025 and beyond to 2033, a more diversified competitive landscape is anticipated. With the entry of generic drugs and the rise of local manufacturers, especially in high-demand regions, collaboration, innovation, and adaptability are set to be the guiding tenets for industry players.

Historical & Forecast Period

This study report represents an analysis of each segment from 2023 to 2033 considering 2024 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2025 to 2033.

The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends & technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. The key data points that enable the estimation of Human Immunodeficiency Virus Therapeutics market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users & consumption volume, price, and value.

Geographical revenues generated by countries considered in the report

Micro and macro environment factors that are currently influencing the Human Immunodeficiency Virus Therapeutics market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top-down and bottom-up approach for validation of market estimation assures logical, methodical, and mathematical consistency of the quantitative data.

  • Market Segmentation
  • Drug Type
    • Branded Drugs
    • Generic Drugs
  • Drug Class
    • Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
    • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • Entry and Fusion Inhibitors
    • Protease Inhibitors (PIs)
    • Integrase Inhibitors
    • Coreceptor Antagonists
  • Region Segment (2023-2033; US$ Million)
  • North America
  • U.S.
  • Canada
  • Rest of North America
  • UK and European Union
  • UK
  • Germany
  • Spain
  • Italy
  • France
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East and Africa
  • GCC
  • Africa
  • Rest of Middle East and Africa

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Human Immunodeficiency Virus Therapeutics market?
  • What are the key investment pockets concerning product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2033.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Human Immunodeficiency Virus Therapeutics market?
  • Which is the largest regional market for Human Immunodeficiency Virus Therapeutics market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Human Immunodeficiency Virus Therapeutics market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Human Immunodeficiency Virus Therapeutics market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Human Immunodeficiency Virus Therapeutics Market
  • 2.2. Global Human Immunodeficiency Virus Therapeutics Market, By Drug Type, 2024 (US$ Million)
  • 2.3. Global Human Immunodeficiency Virus Therapeutics Market, By Drug Class, 2024 (US$ Million)
  • 2.4. Global Human Immunodeficiency Virus Therapeutics Market, By Geography, 2024 (US$ Million)
  • 2.5. Attractive Investment Proposition by Geography, 2024

3. Human Immunodeficiency Virus Therapeutics Market: Competitive Analysis

  • 3.1. Market Positioning of Key Human Immunodeficiency Virus Therapeutics Market Vendors
  • 3.2. Strategies Adopted by Human Immunodeficiency Virus Therapeutics Market Vendors
  • 3.3. Key Industry Strategies

4. Human Immunodeficiency Virus Therapeutics Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Human Immunodeficiency Virus Therapeutics Market Value, 2023 - 2033, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis
  • 4.6. Porter's Five Force Model
    • 4.6.1. Supplier Power
    • 4.6.2. Buyer Power
    • 4.6.3. Threat Of Substitutes
    • 4.6.4. Threat Of New Entrants
    • 4.6.5. Competitive Rivalry
  • 4.7. PESTEL Analysis
    • 4.7.1. Political Landscape
    • 4.7.2. Economic Landscape
    • 4.7.3. Technology Landscape
    • 4.7.4. Legal Landscape
    • 4.7.5. Social Landscape

5. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2024 Versus 2033
  • 5.3. Market Segmentation
    • 5.3.1. Branded Drugs
    • 5.3.2. Generic Drugs

6. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2024 Versus 2033
  • 6.3. Market Segmentation
    • 6.3.1. Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
    • 6.3.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • 6.3.3. Entry and Fusion Inhibitors
    • 6.3.4. Protease Inhibitors (PIs)
    • 6.3.5. Integrase Inhibitors
    • 6.3.6. Coreceptor Antagonists

7. North America Human Immunodeficiency Virus Therapeutics Market, 2023-2033, USD (Million)

  • 7.1. Market Overview
  • 7.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
  • 7.3. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
  • 7.4.Human Immunodeficiency Virus Therapeutics Market: By Region, 2023-2033, USD (Million)
    • 7.4.1.North America
      • 7.4.1.1. U.S.
        • 7.4.1.1.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 7.4.1.1.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 7.4.1.2. Canada
        • 7.4.1.2.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 7.4.1.2.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 7.4.1.3. Rest of North America
        • 7.4.1.3.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 7.4.1.3.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)

8. UK and European Union Human Immunodeficiency Virus Therapeutics Market, 2023-2033, USD (Million)

  • 8.1. Market Overview
  • 8.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
  • 8.3. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
  • 8.4.Human Immunodeficiency Virus Therapeutics Market: By Region, 2023-2033, USD (Million)
    • 8.4.1.UK and European Union
      • 8.4.1.1. UK
        • 8.4.1.1.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 8.4.1.1.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 8.4.1.2. Germany
        • 8.4.1.2.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 8.4.1.2.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 8.4.1.3. Spain
        • 8.4.1.3.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 8.4.1.3.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 8.4.1.4. Italy
        • 8.4.1.4.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 8.4.1.4.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 8.4.1.5. France
        • 8.4.1.5.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 8.4.1.5.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 8.4.1.6. Rest of Europe
        • 8.4.1.6.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 8.4.1.6.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)

9. Asia Pacific Human Immunodeficiency Virus Therapeutics Market, 2023-2033, USD (Million)

  • 9.1. Market Overview
  • 9.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
  • 9.3. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
  • 9.4.Human Immunodeficiency Virus Therapeutics Market: By Region, 2023-2033, USD (Million)
    • 9.4.1.Asia Pacific
      • 9.4.1.1. China
        • 9.4.1.1.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 9.4.1.1.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 9.4.1.2. Japan
        • 9.4.1.2.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 9.4.1.2.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 9.4.1.3. India
        • 9.4.1.3.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 9.4.1.3.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 9.4.1.4. Australia
        • 9.4.1.4.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 9.4.1.4.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 9.4.1.5. South Korea
        • 9.4.1.5.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 9.4.1.5.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 9.4.1.6. Rest of Asia Pacific
        • 9.4.1.6.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 9.4.1.6.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)

10. Latin America Human Immunodeficiency Virus Therapeutics Market, 2023-2033, USD (Million)

  • 10.1. Market Overview
  • 10.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
  • 10.3. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
  • 10.4.Human Immunodeficiency Virus Therapeutics Market: By Region, 2023-2033, USD (Million)
    • 10.4.1.Latin America
      • 10.4.1.1. Brazil
        • 10.4.1.1.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 10.4.1.1.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 10.4.1.2. Mexico
        • 10.4.1.2.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 10.4.1.2.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 10.4.1.3. Rest of Latin America
        • 10.4.1.3.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 10.4.1.3.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)

11. Middle East and Africa Human Immunodeficiency Virus Therapeutics Market, 2023-2033, USD (Million)

  • 11.1. Market Overview
  • 11.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
  • 11.3. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
  • 11.4.Human Immunodeficiency Virus Therapeutics Market: By Region, 2023-2033, USD (Million)
    • 11.4.1.Middle East and Africa
      • 11.4.1.1. GCC
        • 11.4.1.1.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 11.4.1.1.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 11.4.1.2. Africa
        • 11.4.1.2.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 11.4.1.2.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 11.4.1.3. Rest of Middle East and Africa
        • 11.4.1.3.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 11.4.1.3.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)

12. Company Profile

  • 12.1. AbbVie Inc.
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Portfolio
    • 12.1.4. Strategic Initiatives
  • 12.2. Boehringer Ingelheim International GmbH
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Portfolio
    • 12.2.4. Strategic Initiatives
  • 12.3. Bristol-Myers Squibb Company
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Portfolio
    • 12.3.4. Strategic Initiatives
  • 12.4. Cipla Inc.
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Portfolio
    • 12.4.4. Strategic Initiatives
  • 12.5. Genentech, Inc.
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Portfolio
    • 12.5.4. Strategic Initiatives
  • 12.6. Gilead Sciences, Inc.
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Product Portfolio
    • 12.6.4. Strategic Initiatives
  • 12.7. Merck & Co., Inc.
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Product Portfolio
    • 12.7.4. Strategic Initiatives
  • 12.8. ViiV Healthcare
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Product Portfolio
    • 12.8.4. Strategic Initiatives
  • 12.9. Others
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Product Portfolio
    • 12.9.4. Strategic Initiatives